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AbstractTwo studies were conducted to examine the range of virus neutralizing serum antibody (VNSA) response after vaccination 
with a modified-live viral vaccine in cattle and the level of protection elicited when subsequently challenged with a highly 
virulent type 2 BVDV. Study 1 examined responses in colostrum deprived (CD) calves with no passively acquired antibodies whereas Study 2 examined responses in conventionally raised (CR) calves which had varying levels of passive antibodies prior to vaccination. Study 1 used CD calves averaging 120 days of age. For Study 2, calves averaged 130 days of age and 
were stratified into CR-Low, Mid and High response groups based response to vaccination. Grouping was based on standard 
deviations from the mean value obtained from ELISA assay and reconfirmed by virus neutralization. Twelve calves, from each Rep in Study 2, were selected to represent low, mid and high response groups (n = 4 calves per group). The VNSA values 
for the three groups were as follows; CR-Low (titer < 1:4), CR-Mid (titer 1:4 to 1:16) and CR-High (titer > 1:16). Calves were 
challenged with a high virulence BVDV2 strain. Samples were collected for both studies on days -2, 2, 4, 6, 9, 11 and 13 post challenge to determine levels of circulating white blood cells, virus isolation and levels of BVDV VNSA. While, overt respira-tory or enteric disease was not observed in any of the vaccinated calves, clinical symptoms were more likely to be observed 
in calves with lower BVDV VNSA levels following the BVDV challenge demonstrating significant association between VNSA 
levels and clinical protection. However, the extent of clinical symptoms including decreases in WBC and pyrexia, were more 
severe in the non-vaccinated animals which indicates vaccination did provide a level of protection.
Keywords: Bovine Viral Diarrhea Virus; Vaccination; Serology
Abbreviations
IBR: Bovine Herpesvirus Type-1;
BRDC: Bovine Respiratory Disease Complex; 
BRSV: Bovine Respiratory Syncytial Virus; 
BVDV: Bovine Viral Diarrhea Virus; 
BVDV1: Bovine Viral Diarrhea Virus Type 1; 
BVDV2: Bovine Viral Diarrhea Virus Type 2; 
BC: Buffy Coat; 
CD: Colostrum Deprived; 
CR: Conventionally Raised;
ELISA: Enzyme-Linked Immunosorbent Assay; 
GMT: Geometric Mean Titer; 
MDBK: Madin Darby Bovine Kidney; 
Mab: Maternal Antibodies; 
MLV: Modified Live Vaccine; 
NC: Non-Vaccinated/Challenged; 
NN: Non-Vaccinated/Non-Challenged; 
PI3: Parainfluenzavirus-3; 
RNA: Ribonucleic Acid; 
TCID: Tissue Culture Infectious Dose; 
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IntroductionBovine respiratory disease complex (BRDC) is a major burden 
to the beef industry. The level of difficulty in control is evi-dence by the incidence of disease remaining steady over the past 10 years despite vaccination and other control measures 
as reported by the National Animal Health Monitoring Service [1]. A common agent included in many of the commercially available vaccines to control viral pathogens associated with the BRDC is bovine viral diarrhea virus (BVDV). Vaccines con-
taining BVDV have been available since 1967 [2] and current-
ly there are over 160 BVDV modified-live vaccines (MLV) and killed vaccines commercially available in the United States [3]. Although vaccines have been in use for over 40 years, losses 
associated with BVDV remain significant.While vaccination confers a level of herd protection it is not successful at effectively eliciting protection for each individu-
al animal [4]. One potential reason for lack of vaccine efficacy 
is the presence and variability of maternal antibodies (MAb) 
at the time of vaccination. The interference between MAb and production of a humoral response to infection or vaccination 
with modified live or killed vaccination has been previously 
demonstrated [5]. Therefore, varying levels of MAb at the time 
of vaccination could reduce efficacy of the vaccine and induce increased variability in response to vaccination, predisposing 
calves to be more susceptible to infection. Humoral antibod-
ies are widely used to measure the efficiency of vaccines as a 
correlate to protection. While the absolute level of Ab required to prevent disease is unknown, it has been demonstrated that 
passively acquired immunity with Ab titers of 1:16 would pro-tect animals against BVDV clinical disease but not viral shed-
ding [6]. Therefore, there is a need to understand if vaccina-
tion in the face of MAb impact the level of protection conferred when calves are challenged later in life due to the variation in the humoral Ab response.   The objectives of these studies were to determine the range 
of humoral response after vaccination with a modified-live vaccine for cattle managed in a conventional beef operation 
and in age matched colostrum deprived (CD) calves. In addi-tion, the level of protection associated with different humoral response levels was evaluated based on challenge with a high 
virulent strain (BVDV2-1373) of BVDV. To this end, CD calves (no Ab) managed under controlled settings and conventionally raised (CR) categorized into low, mid and high antibody titer response groups following vaccination were used. Both CD 
and CR vaccinated calves were subsequently exposed to a high virulence BVDV. Clinical presentation (pyrexia), viremia and immunosuppression (leukopenia) were compared in all cattle following the challenge. 
Materials and Methods
Handling and treatment of all cattle utilized for this study com-
plied with the Animal Welfare Act as amended (7 USC, 2131-
2156).Studies were conducted to evaluate the response to vaccina-tion in CD calves not allowed colostrum, and CR calves that were left with their dams and allowed colostrum.  The purpose of the CD calf study was to determine vaccination response in the complete absence of maternal antibodies. The responses in the CD calves were compared to the responses in typical pro-
duction CR calves that can have variability in the timing, qual-ity and amount of colostrum they receive impacting levels of 
circulating MAb present at vaccination. The CD calves provided a clear response to the vaccination without interference from 
passive immunity while the CR calf study reflected vaccination response under conventional production practices. The same 
commercially available 5-way MLV vaccine was used for both studies.
Study #1 (CD calves)
Eight CD Holstein bull calves were procured at approximate-ly 120 days of age and allowed to acclimate to the facility for approximately 1 week. Calves were group housed based on 
experimental group; CD non-vaccinated/non-challenged (CD-
NN; n=2), CD non-vaccinated/challenge (CD-NC; n=2) and CD 
vaccinated/challenged (CD-VC; n=4). Vaccinated calves were 
given 2 ml of a 5-way commercially available MLV containing 
strains of BVDV1, BVDV2, bovine herpesvirus type-1 (IBR), 
parainfluenzavirus3 (PI3) and bovine respiratory syncytial vi-
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and body temperatures were recorded daily beginning at -2 
days post-exposure. Clinical illness scores were based on the 
University of Wisconsin-Madison calf health scoring criteria for calves [8]. 
Samples were collected on days -2, 0, 2, 4, 6, 9, 11 and 13 
post-inoculation in both studies for determination of circulat-
ing white blood cell (WBC) counts, VNSA titers and VI. Blood samples for WBC counts were collected in buffered sodium 
citrate and WBC counts were determined using an HV 1500 
cytometer (CDC Technologies, Inc., Oxford, CT) following the 
manufacturer’s directions. Results from days -2 and 0 for WBC counts were used to generate baseline values. Serum samples were collected in serum separation tubes with gel and clot activator. Titers for VNSA were determined, using 
BVDV2-296c and BVDV1-Singer strain as described previously 
[7].Nasal swabs and buffy coat samples were collected on the 
same days and used for VI. For VI from buffy coat, blood was collected in sodium heparin tubes and BC was separated by 
centrifugation (800 x g, 20 min) and put through one freeze/
thaw cycle (-20 °C/25 °C). A 250 µl aliquot of BC freeze/thaw 
lysate was mixed with 250 µl media. The resulting mixture was 
used to inoculate a 10 cm2, 60-70% confluent, flask of Madin 
Darby bovine kidney (MDBK) cells. After rocking at 37 °C for 1 h, the inoculum was removed from the cells and replaced with 3 ml of cell culture media. Four days later, the cell culture (in-
cluding media) was frozen at -80 °C. Upon thawing to 25 °C, 
500 µl of the resulting lysate was added to a fresh 10 cm2 flask 
of MDBK cells. Flasks were rocked for 1 h at 37 °C and 3 ml of cell culture media was added. After incubating for 4 days, to-tal ribonucleic acid (RNA) was extracted from the culture and 
tested for BVDV as described [9].
Nasal swabs were collected via nylon flocked swabs by swip-ing the mucosal surface. Swabs were placed in micro tubes and 
stored at -20 °C. For reconstitution 1 ml of cell culture media 
was added to the tube with the swab, vortexed for 10-15 s then allowed to sit for 1 h prior centrifuging at 800 x g for 5 min. Of 
the resulting supernatant 500 µl was used to inoculate a 10 cm2, 60-70% confluent, flask of MDBK cells. Flasks were treat-ed in the same manner from this point forward as described in 
the previous paragraph for BC description of VI. 
Virus
The virulent strain BVDV2-1373, isolated from a severe acute BVDV outbreak in Ontario, Canada [10] was used as the chal-lenge strain in both studies. The virus was determined non-
cytopathic by amplification characteristics in culture epitheli-al cells [11] and no evidence of cleavage of the viral protein, 
NS2/3 [12]. This strain reproducibly causes severe acute dis-
rus (BRSV) at an average age of 120 days by subcutaneous in-jection. The CD calves did not receive a booster vaccination as 
recommended by the product label, for calves under 6 months of age, due to no maternal antibody interference. The initial vaccination was administered at a similar age as conventional-ly raised calves used in Study #2. 
Study #2 (CR calves)Two replicates of this study, Rep 1 and Rep 2, were conducted using fall and spring born calves raised under typical produc-
tion practices. Calves in Rep 1 (216 spring born beef calves, 
177.03 ± 30.05 kg body weight), were given an initial vacci-
nation with the same commercially available 5-way MLV at an average age of 150 days. Calves in Rep 2 (120 fall born beef 
calves, 141.06 ± 29.43 kg BW), were given the initial vaccina-
tion, with the same vaccine, at an average age of 107 days. A booster vaccination was administered with the same product 20 days after the initial vaccination in both replicates. A serum sample was collected to characterize the response to vaccination 20 days after booster vaccination (40 days after ini-tial vaccination). For initial screening level of serum antibodies 
against BVDV was initially evaluated using a commercial ELISA 
(BioX ELISA; BioX Diagnostics, Belgium, Europe) for prelimi-
nary classification into vaccination response groups. Criteria for high and low titer response were values one standard devi-ation above and below the mean by replicate, respectively. Cri-teria, for the mid response group comprised levels within one standard deviation of the mean by replicate. Sera from select-ed animals in each response group were tested by virus neu-
tralization, as described previously [7] using reference strains 
BVDV2-296 and BVDV1-Singer, to determine the titer of VNSA 
present. Serial log2 base dilutions were performed from 1:2 to 
1:256. Samples were considered positive with VNSA titer ≥1:2 
and expressed as geometric mean titer (GMT) with dilution of 
1:2 and 1:256 coinciding with GMT of 1 and 8, respectively. Conventionally raised (CR) calves, used in this study, were transported to the containment barn approximately 1 week prior to the start of the study to acclimate to the facility. All CR calves, regardless of vaccination response, were group housed during the course of the study.
Challenge studies and samplingPrior to the start of both studies all calves were tested negative for BVDV in buffy coat (BC) and ear notches samples by virus 
isolation (VI) and enzyme-linked immunosorbent assay (ELI-
SA; Herdcheck BVD-PI, IDEXX Laboratories Inc., Westbrook, 
Maine), respectively. All calves were inoculated with 5 ml of 
BVDV2-1373 inoculum [2.5 ml / nostril; titer of 1 X 106 ml-1 
tissue culture infectious dose (TCID)] intranasally. Visual ap-praisals for signs of clinical illness were monitored each day 
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ease in calves seronegative to BVDV [13]. Viral stocks were propagated as previously described [14] with the exception 
that the MDBK cell line was used rather than bovine turbinate cells. Fetal bovine serum used to supplement the culture medi-um was tested free of BVDV antigen and antibodies [15]. 
Statistical analysis
Mean WBC measures were compared between antibody re-
sponse groups using GLM model in SAS (SAS Institute Inc., 
Cary NC; v 9.2). Means were separated and tested using Fish-
ers least significance difference test and differences were 
considered significant for p values <0.05. The correlation pro-cedure (PROC CORR) in SAS was utilized to test correlations 
between variables of interest and significance was assumed at 
the p <0.05 level. 
Because no significant differences were detected between Rep 1 and 2 in Study 2 for all measurements in the CR calves, Reps 1 and 2 results were combined.
Results
Titers prior to challengeOnly BVDV Type 2 titers will be reported since the challenge was a Type 2 BVDV and the same trends were observed for 
Type 1 BVDV titers. On d -2 prior to challenge non-vaccinated 
CD calves (CD-NN and CD-NC treatment groups) had no detect-able VNSA titer to Type 2 BVDV (Figure 1). The CD vaccinated 
calves (CD-VC) had a titer as measured by virus neutralization 
at 7.8 (log base 2 scale; Figure 1). 
Figure 1. Comparison of BVDV2 296c virus neutralizing serum an-tibody titer for both colostrum deprived (CD) and conventionally raised (CR) calves in each respective treatment response group on 
day -2 prior to challenge and 13 days following inoculation with 
BVDV2-1373.
On day -2 post challenge the VNSA titers for CR calves were 
consistent with their segregation into groups of CR-Low, Mid 
and High titers. There was approximately a 2 fold difference between each respective titer group, with titers measured at 
1.45, 3.26 and 5.65 for the CR-Low, Mid and High groups re-spectively (Figure 1). Contrasts between the 2 studies would highlight that while all vaccinated calves, regardless of CD or CR groups, did have de-
tectable titers; calves in the CD-VC group did have the highest 
titer at 7.8 versus 5.65 in the CR-High group (Figure 1). This 
would suggest that MAb interference could have played a role in the vaccination responses observed in the CR calves.
Post challenge measures
Post challenge measures consist of; pyrexia defined as a 1°C above baseline temperature, viral shedding, viremia, and im-
munosuppression (measured by a 20% decline in total circu-
lating WBC). For calves in the CD-NN and CD-VC groups pyrex-ia was not detected, virus was not in nasal secretions or in BC 
samples (viremia) and total WBC counts fluctuated minimally. 
WBC counts did not drop below 20% of the baseline values 
(Table 1 and Figure 2). Conversely, calves in the CD-NC group pyrexia was observed, virus was isolated from both nasal se-cretions and BC samples. On day 2 post challenge a greater 
than 20% decline for total circulating WBC was detected (Ta-ble 1 and Figure 2). Pyrexia, viral shedding in nasal secretions, and viremia was sustained over the course of the study as well 
as a continual decline with no recovery for WBC with a 68% observed decline from baseline value on day 13 post challenge. Regardless of titer response group in the CR calves, all cattle 
exhibited pyrexia averaging 2.75, 5 and 3.8 days for the CR-
High, Mid and Low groups respectively. Similarly, virus was isolated from both BC and nasal swab for calves in all response groups following challenge. There was no trend associated with vaccination response groups and day of viral shedding or 
viremia in the CR calves. Calves in the CR-High and Mid groups 
had a total circulating WBC decline of 21% at one sampling 
date, days 9 and 4, respectively. The CR-High calves returned to 
baseline values on day 11 and the CR-Mid returned to baseline 
values on day 6 post-challenge. In contrast, calves character-
ized as CR-Low had an initial decline for total circulating WBC 
of 36% on day 4 with sustained WBC suppression greater than 
20% through day 11 (27%) returning to baseline values by day 
13 post-challenge. Contrasts between the two studies for post challenge mea-
sures revealed interesting differences between the CD-VC and 
the CR- Low, Mid and High groups (Table 1). While a positive sample for either viremia or viral shedding was detected on at least 1 day during the 13 day post challenge period for all CR 
calves, no positive samples were detected in the CD-VC calves. The differences in vaccination response between the 2 studies 
were also reflected in the percent decline from baseline values 
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post challenge (Figure 3). The initial increase associated with 
the anamnestic response was first observed on day 6 with the 
majority of calves in the CR-Mid and High groups reaching 
peak titers by day 9 and calves in the CR-Low reaching similar peak titer on day 13 post challenge (Figure 3).
Figure 2. (a) Total circulating white blood cells (WBC) for colostrum deprived (CD) calves in each respective treatment response group fol-
lowing inoculation with BVDV2-1373. (b) Total circulating WBC for conventionally raised calves in each respective titer response group 
following inoculation with BVDV2-1373.
Figure 3. Change in BVDV2-296c virus neutralizing serum antibody titer for conventionally raised (CR) calves in each respective titer re-
sponse group following inoculation with BVDV2-1373.
for WBC counts as the CD-VC calves had the least decline at 
only 15.78 percent compared to 36.27, 21.6 and 20.94 percent 
for the CR-Low, Mid and High groups, respectively (Figure 2). 
Calves in the CD-NN group which served as the control only had a decline of 12.11 percent over the course of the post chal-lenge period. 
Table 1. Temperature and viral shedding evaluation during the chal-lenge period for colostrum deprived (CD) and conventionally raised (CR) calves.
Anamnestic response post challenge
The CD-NN had no detectable VNSA titers throughout the 
study period. Calves in the CD-NC group did have a titer of 3.7 
13 days post-challenge compared to no detectable titer prior 
to the challenge and the CD-VC calves had a slight anamnestic 
response with the increase in titer from 7.8 on day -2 to 8.5 13 days after the challenge (Figure 3). 
An anamnestic response was observed for all calves in the CR-
Low, Mid and High titer response groups with all 3 groups hav-
ing comparable titers 7.8, 8.48 and 8.1 respectively, on day 13 
Jacobs Publishers 5
Cite this article:  Falkenberg S M. Association of Serum Antibody Levels Following Vaccination with A Modified Live BVDV Vaccine and Protection from Clinical Disease upon Challenge. 
 J J Vaccine Vaccination. 2015, 1(1): 002.
Table 1.    
Temperature and viral shedding evaluation during the challenge period for 
colostrum deprived (CD) and conventionally raised (CR) calves  
 Response groups 
  
 
CR-High CR-Mid CR-Low 
# calves with pyrexia 4/7*† 5/8 5/7*† 
Average days of pyrexia 2.75 5 3.8 
Highest temperature 40.3 41.0 41.1 
Viremia and shedding 8/8 8/8 8/8 
    
 CD-NN CD-VC CD-NC 
# calves with pyrexia 0/2 0/4 2/2 
Average days of pyrexia 0/2 0/4 11 
Highest temperature 39.1 39.3 41.3 
Viremia and shedding n/a 0/4 2/2 
 
*Pyrexia defined as 1 °C above average baseline temperatures 
†No temperature data for 1 calf 
No major differences for titers post challenge were observed between the two studies for the vaccinated calves in the CD or CR groups (Figure 1). 
DiscussionPrevious studies have evaluated protective immunity for cattle 
vaccinated against BVDV [16-18] as well as the effect of ma-
ternal antibodies on achieving passive immunity [17,18], and 
have concluded that circulating antibodies are protective. Ma-ternal derived antibodies elicit passive immunity that serves as 
the first line of defense until a fully functional immune system is present, but circulating maternal antibodies can vary at the 
time of calf-hood vaccination and contribute to the variability in response to vaccination. 
In these studies we used two approaches using CR and CD calves to understand the level of protection elicited by vaccina-tion. Regardless the level of VNSA in response to vaccination, calves that were vaccinated in either the CR or CD study expe-rienced a shorter length of pyrexia, decreased number of days with viremia and viral shedding, and less of a WBC count de-
cline compared to CD-NC calves. The greatest percent decline regardless of day post challenge was averaged for all vaccinat-
ed calves (CD and CR) and was 23.65% as compared to 72.51% 
for the CD-NC calves. This suggests that vaccination, in the face 
of or lacking circulating MAb at the time of vaccination, did de-crease clinical disease and agree with studies comparing pro-
tected and unprotected calves [16,18]. While vaccination did reduce clinical presentation, it did not eliminate viral replication. Viremia and viral shedding was detected in all vaccinated CR calves, based on isolation from 
nasal swabs and BC samples, up to day 9 post challenge. There 
were no significant differences (p>0.05) noted for clinical pre-
sentation between titer response groups (Low, Mid and High), general trends for the low response group were a greater de-
crease in WBC (36.27% decline for the CR-Low compared to 
21.6 and 20.94 for the CR-Mid and High groups, respectively), when compared to baseline values, and throughout the course of the experiment and highest body temperature was recorded for this group. Suggesting while Ab titers are in the protective range calves with a weaker vaccination response are more sus-ceptible. Cattle were initially categorized based on titer response to booster vaccination, but a trend observed was the onset of anamnestic response in the low response group with animals not reaching peak titer until later during the trial period. Cat-
tle were subsequently re-classified based on the anamnestic 
response into groups that reached peak of VNSA level by day 6, 
9, or 13 post-challenge (Table 2). Only cattle from study 2 were 
included in this analysis. In both Rep 1 and Rep 2, in study 2, 
the earliest anamnestic response group (day 6 compared to 
day 13) correlated with less of a decline in WBC. The average 
maximum percent decrease in circulating WBC for day 6, 9 and 
13 was -22.9%, -38.2%, and -44.9%, respectively. The cattle 
that had higher antibody titers by day 6 had significantly less (p=0.005) WBC decline compared to calves with peak titers on 
day 9 and 13 (Table 2). While WBC decline in the vaccinated 
calves was not as drastic as decline observed in the CD-NC, vaccinated calves did have a decline in WBC due to the BVDV challenge and a correlation can be observed in WBC decline and peak titer day. Cattle in this study that had earlier anam-
nestic response (day 6) also demonstrated reduced severity of clinical signs based on the evaluated criteria (Table 2). While this is a broad snapshot of anamnestic responsiveness with-in this group of cattle, data from this study suggests potential 
relationships with humoral response profiles and severity of disease upon challenge.
Table 2. Groups redefined by day of anamnestic response following BVDV challenge.Data from this study exhibits the variability and extremes or outliers in regard to titers that can be expected in response to vaccination. Understanding variation in response to vaccina-tion, while broadly categorized in this study, is a step in char-acterizing the level of protection that can be expected to be conferred after vaccination.
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Table 2.      
Groups redefined by day of anamnestic response following BVDV 
challenge  
  
Anamnestic 
response 
groups  
Number 
of calves 
per group 
Max % 
Decrease 
WBC 
Day Max 
Decrease 
WBC* 
Max 
Temp 
(°C) 
Rep 1† 
Day 6 1 -15.9a 9.0 39.5 
Day 9 7 -34.1a 6.4 40.0 
Day 13 4 -40.2a 10.5 40.4 
      
Rep 2‡ 
Day 6 4 -24.6a 12.5 39.1 
Day 9 4 -45.4b 3.0 40.2 
Day 13 4 -49.6b 4.5 40.2 
      
Total§ 
Day 6 5 -22.9a 11.8 39.2 
Day 9 11 -38.2b 5.2 40.0 
Day 13 8 -44.9b 7.5 40.3 
 
*Average day the maximum decrease was observed for WBC 
†p=0.24 
‡p=0.002 
§All vaccinated cattle included from Rep 1 and Rep 2 (p=0.005) 
abGroup means differ in each column for each replicate or total 
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